A Case Series of Patients with Pancreatic Cancer and Cholangiocarcinoma Treated with nab-Paclitaxel at a Single Institution

Michael P. Kolinsky, Michael B. Saywer, Jennifer L. Spratlin

Department of Medical Oncology, Cross Cancer Institute, Edmonton, Canada.

DOI: 10.4236/jct.2014.56069                

Abstract

Background: Locally advanced or metastatic pancreatic cancer patients have a poor prognosis with median survival less than 12 months. Nanoparticle albumin bound (nab)-paclitaxel is a novel agent that has demonstrated antitumor effects in cancers that overexpress the albumin binding protein SPARC (secreted protein acidic and rich in cysteine), which includes pancreatic cancer. A recent phase III trial comparing nab-paclitaxel and gemcitabine to gemcitabine alone demonstrated a survival advantage in patients with previously untreated metastatic pancreatic cancer. Here we present our local experience with this drug in patients with gastrointestinal malignancies. Methods: Patients treated with nab-paclitaxel for gastrointestinal malignancies at the Cross Cancer Institute in Edmonton, Alberta, Canada were identified and these patient’s medical records were interrogated for data. Results: Three patients with pancreatic cancer and two with cholangiocarcinoma have been treated with nab-paclitaxel at the Cross Cancer Institute. Three patients achieved stable disease, while one had a partial response, and one had progressive disease after the first assessment. Median time to progression was 3.7 months. Median overall survival (OS) was 32.5 months. Median OS from initiation of nab-paclitaxel was 7.2 months. Patients tolerated treatment with nab-paclitaxel well with only one patient requiring treatment modification due to neutropenia. Conclusion: The experience at this single center supports published evidence that nab-paclitaxel is a safe and effective therapy in pancreatic cancer, but also suggests that it may have activity in cholangiocarcinoma, which to our knowledge is the first published evidence of this in humans.

Keywords

nab-Paclitaxel, Pancreatic Cancer, Cholangiocarcinoma, Case Series

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Canadian Cancer Society’s Advisory Committee on Cancer Statistics (2013) Canadian Cancer Statistics. Canadian Cancer Society, Toronto. http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer %20statistics/canadian-cancer-statistics-2013-EN.pdf
[2]	Neoptolemos, J., Stocken, D., Friess, H., Bassi, C., Dunn, J.A., Hickey, H., et al. for the European Study Group for Pancreatic Cancer (2004) A Randomized Trial of Chemoradiotherapy and Chemotherapy After Resection of Pancreatic Cancer. The New England Journal of Medicine, 350, 1200-1210. http://dx.doi.org/10.1056/NEJMoa032295
[3]	Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y., et al. for the Groupe Tumeurs Digestives of Unicancer and the PRODIGE Intergroup (2011) FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. The New England Journal of Medicine, 364, 1817-1825. http://dx.doi.org/10.1056/NEJMoa1011923
[4]	Alberta Health Services Pancreatic Cancer Clinical Practice Guideline. http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-gi006-pancreas.pdf
[5]	Burris, H., Moore, M., Andersen, G., Green, M.R., Rothenberg, M.L., Modiano, M.R., et al. (1997) Improvements in Survival and Clinical Benefit with Gemcitabine as First-Line Therapy for Patients with Advanced Pancreas Cancer: A randomized trial. Journal of Clinical Oncology, 15, 2403-2413.
[6]	Tempero, M.A., Berlin, J., Ducreux, M., Haller, D., Harper, P., Khayat, D., et al. (2011) Pancreatic Cancer Treatment and Research: An International Expert Panel Discussion. Annals of Oncology, 22, 1500-1506. http://dx.doi.org/10.1093/annonc/mdq545
[7]	Von Hoff, D.D., Ramanathan, R., Borad, M., Laheru, D.A., Smith, L.S., Wood, T.E., et al. (2011) Gemcitabine plus nab-Paclitaxel is an Active Regimen in Patients with Advanced Pancreatic Cancer: A Phase I/II Trial. Journal of Clinical Oncology, 29, 4548-4554. http://dx.doi.org/10.1200/JCO.2011.36.5742
[8]	Podhajcer, O., Benedetti, L., Girotti, M., Prada, F., Salvatierra, E. and Llera, A. (2008) The Role of the Matricellular Protein SPARC in the Dynamic Interaction Between the Tumor and the Host. Cancer and Metastasis Reviews, 27, 691-705. http://dx.doi.org/10.1007/s10555-008-9146-7
[9]	Framson, P. and Sage E. (2004) SPARC and Tumor Growth: Where the Seed Meets the Soil? Journal of Cellular Biochemistry, 92, 679-690. http://dx.doi.org/10.1002/jcb.20091
[10]	Desai, N., Trieu, V., Damascelli, B. and Soon-Shiong, P. (2009) SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. Translational Oncology, 2, 59-64. http://dx.doi.org/10.1593/tlo.09109
[11]	Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., et al. (2006) Increased Antitumoral Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared with Cremophor-Based Paclitaxel. Clinical Cancer Research, 12, 1317-1324. http://dx.doi.org/10.1158/1078-0432.CCR-05-1634
[12]	Gelderblom, H., Verweij, J., Nooter, K. and Sparreboom, A. (2001) Cremophor EL: The Drawbacks and Advantages of Vehicle Selection for Drug Development. European Journal of Cancer, 37, 1590-1598. http://dx.doi.org/10.1016/S0959-8049(01)00171-X
[13]	Gradishar, W. (2006) Albumin-Bound Paclitaxel: A Next-Generation Taxane. Expert Opinion on Pharmacotherapy, 7, 1041-1053. http://dx.doi.org/10.1517/14656566.7.8.1041
[14]	Frese, K., Neesse, A., Cook, N., Bapiro, T.E., Lolkema, M.P., Jodrell, D.I. and Tuveson, D.A. (2012) nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer. Cancer Discovery, 2, 260-269.
[15]	Von Hoff, D.D., Ervin, T., Arena, F., Chiorean, E.G., Infante, J., Moore, M., et al. (2013) Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. The New England Journal of Medicine, 369, 1691-1703. http://dx.doi.org/10.1056/NEJMoa1304369
[16]	Eisenhauer, E., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. (2009) New Response Evaluation Criteria in Solid Tumors: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247. http://dx.doi.org/10.1016/j.ejca.2008.10.026
[17]	Valle, J., Wasan, H., Palmer, D., Cunningham, D., Anthoney, A., Maraveyas, A., et al. (2010) Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. The New England Journal of Medicine, 362, 1273-1281. http://dx.doi.org/10.1056/NEJMoa0908721